Themis Medicare and its subsidiary Gujarat Themis Biosyn have called off their merger plan.

Gujarat Themis Biosyn will now focus on boosting its fermentation-based pharma intermediates and API business via capacity expansion and partnerships.

Meanwhile, Themis Medicare will prioritize strengthening its core domestic formulations segment for steady growth.

This strategic pivot aims to unlock greater value by capitalizing on each entity’s core competencies separately.